ArticleEuropean radiology2025
Prediction of thyroid malignancy risk using clinical and ultrasonography features and a machine learning approach.
Article in European radiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aims to develop and validate a predictive model for thyroid nodule malignancy risks using clinical and ultrasonography features and a machine learning (ML) approach.
methodsThis retrospective study is based on the clinical and ultrasound characteristics of 1035 thyroid nodules (845 benign and 190 malignant) to develop and validate the risk prediction model. Employing multiple logistic regression, key features were selected in developing the model. Eight ML algorithms were evaluated for predicting the risks of malignancy. Finally, the predictive ability of the best-performing algorithm was compared against American College of Radiology Thyroid Imaging Reporting and Data System (ACR TI-RADS) and American Thyroid Association (ATA) guidelines.
resultsBased on AUC criteria (88.3, 95% CI: 81.2-94.2), sensitivity (84.2, 95% CI: 71.1-94.7), specificity (92.3, 95% CI: 88.2-95.9), positive predictive value, (71.4, 95% CI: 60.4-83.3) and negative predictive value (96.3, 95% CI: 93.5-98.8), the XGBoost algorithm exhibited superior performance over the other ML algorithms and ACR TI-RADS and ATA. These criteria were obtained for ACR TI-RADS at 54.2%, 63.2%, 48.5%, 21.1%, and 84.8%, while for ATA, they were 44.3%, 76.3%, 27.2%, 18.4%, and 81.6%. In addition, the unnecessary fine-needle aspiration (FNA) rate with ACR TI-RADS and ATA was 43% and 63%, respectively-significantly higher than the 7% obtained with XGBoost.
conclusionsThis study demonstrated the capability of ML approaches in enhancing the accuracy of predicting thyroid malignancy risks as well as their potential benefits in optimizing healthcare resources by reducing unnecessary FNA rates. Using the proposed model through a web-based tool can facilitate clinical judgments in thyroid nodule management and personalized treatment. KEY POINTS: Question Current risk assessment systems have limitations, with high unnecessary FNA rates compared to machine learning (ML) models. Findings The XGBoost algorithm was compared to other ML algorithms, ACR TI-RADS, and ATA and demonstrated superior performance. Clinical relevance This study demonstrated the capability of ML approaches in enhancing the accuracy of predicting thyroid malignancy. The proposed web-based tool to facilitate the prediction of thyroid nodule risk is available at https://aimedlab.ir/tnr .
Indexed as
Identifiers
39948211What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.